Compare INTG & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTG | INKT |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 70.6M |
| IPO Year | 1995 | 2021 |
| Metric | INTG | INKT |
|---|---|---|
| Price | $33.24 | $12.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 27.0K | ★ 43.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $74,753,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.91 | ★ N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $10.37 | $6.80 |
| 52 Week High | $43.84 | $76.00 |
| Indicator | INTG | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 51.44 |
| Support Level | $31.41 | $10.79 |
| Resistance Level | $32.97 | $12.68 |
| Average True Range (ATR) | 2.89 | 1.00 |
| MACD | -0.62 | 0.04 |
| Stochastic Oscillator | 14.77 | 51.07 |
The Intergroup Corp is a company operating in the real estate sector. It was formed to buy, develop, operate, rehabilitate, and dispose of real property of various types and descriptions, as well as to engage in other related business and investment activities. The company operates through three segments: Hotel, Real Estate, and Investment Transactions. The Hotel Operations segment, which generates the majority of the revenue, covers the operation of the Hilton hotel and garage. The Real Estate Operations segment involves the management of multifamily rental properties, while the Investment Transactions segment includes investments of cash in marketable securities and other assets.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.